article thumbnail

Elacestrant 

New Drug Approvals

1] [8] Pharmacokinetics Elacestrant has an oral bioavailability of approximately 10%. [1] 1] [4] It is taken by mouth. [1] 1] [4] Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors , which are the biological targets of endogenous estrogens like estradiol. [1] 3] [7] PATENTS Cruskie MP, et al.

FDA 62
article thumbnail

The essential role of recombinant phage display antibody libraries

Drug Target Review

Overcoming traditional antibody generation limitations with recombinant technologies Antibodies remain essential tools in this ever-changing field for preclinical bioanalysis and drug monitoring through ligand-binding assays (LBAs). FDA no longer needs to require animal tests before human drug trials [Internet]. www.science.org.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advanced 3D cell-based technologies

Drug Target Review

Pharmaceutical companies adapted the usage of organoids derived from specific patient derived tumours in cancer drug screening process for testing drug toxicities and efficacy. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. Nature Cancer.

article thumbnail

How Improving Diversity Can Benefit Clinical Trials

Alta Sciences

Why Diversity in Clinical Trials Matters A wide variety of factors, from age or biological sex to environmental conditions and lifestyle choices (e.g., substance abuse, sexual activity), can influence the risk and likelihood of developing a disease or other long-term health issues—as well as the way an individual responds to treatment.

article thumbnail

Rezafungin

New Drug Approvals

7] This pharmacokinetic property has supported its investigation for the treatment of deep-seated Candida infections, including osteomyelitis. [8] 2] It is an echinocandin antifungal [1] [4] that acts as a fungal -glucan synthase inhibitor. [5] 2] [3] CAS No. 2] The applicant for this medicinal product is Mundipharma GmbH. [2] 23 March 2023.

article thumbnail

Probenecid

New Drug Approvals

7] Pharmacokinetics In the kidneys , probenecid is filtered at the glomerulus , secreted in the proximal tubule and reabsorbed in the distal tubule. Probenicid lowers the concentration of certain drugs in urine drug screens by reducing renal excretion of these drugs. . Probenecid also inhibits pannexin 1. [7]

article thumbnail

Trospium chloride

New Drug Approvals

octane-8,1′-azolidin-1-ium]-3-yl 2-hydroxy-2,2-diphenylacetate;chloride FDA 2024, Cobenfy 9/26/2024, To treat schizophrenia Press Release Drug Trials Snapshot Trospium chloride is a muscarinic antagonist used to treat overactive bladder. [3] “Clinical pharmacokinetics of trospium chloride” Clin Pharmacokinet.